VENTANA MET (SP44) RxDx Assay
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) · Decision date Oct 23, 2026
What did the FDA approve?
FDA approved a labeling change for the VENTANA MET (SP44) RxDx Assay under supplement S003. The change adds results from supplemental data in Post-Approval Study Report P240037/R004 concerning use of SurePath for preparation of cytology specimens.
This is a Normal 180 Day Track supplement with no user fee, classified as a Labeling Change - PAS. The decision does not represent a new approval of the assay system itself. The statement reports the purpose of the labeling update but does not independently establish safety or clinical effectiveness.
FDA approval order statement
Approval to update the labeling for the VENTANA MET (SP44) RxDx Assay to include results of supplemental data provided in the Post-Approval Study (PAS) Report P240037/R004 for utilization of SurePath for preparation of cytology specimens.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Pathology
- Decision date
- Oct 23, 2026
- FDA change category
- Labeling Change - PAS
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240037/S003
- Regulatory pathway
- PMA supplement
- Product code
- SER
- Decision code
- APPR
- Decision date
- Oct 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Immunohistochemistry Assay, Antibody, MET.
- Product code
- SER
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240037. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240037 · Original PMA
VENTANA MET (SP44) RxDx Assay
P240037/S003 received
Application receipt date recorded by FDA.
P240037/S003 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P240037. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240037
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) | PMA approval | May 14, 2025 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1910 E. Innovation Park Dr., Tucson, AZ, 85755
Sources and methodology
- Original FDA record: P240037/S003
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records